Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]flumazenil is a radiolabeled analog of flumazenil used as a positron emission tomography (PET) imaging agent. It specifically binds to the benzodiazepine site of the gamma-aminobutyric acid type A (GABA_A) receptor in the brain. The compound is labeled with fluorine-18 (^18F), which provides a longer half-life than carbon-11-labeled flumazenil and allows for broader clinical use. Its primary application is in neuroimaging to assess GABA_A receptor distribution and density, particularly for localizing epileptogenic zones in drug-resistant temporal lobe epilepsy and evaluating cortical damage in conditions such as stroke, alcoholism, and Alzheimer’s disease[2][3][4][6][9]. Unlike therapeutic flumazenil (used as an antidote for benzodiazepine overdose), [18F]flumazenil serves exclusively as a diagnostic radiopharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]flumazenil.